Skip to main content
Clinical Trials/NCT01878643
NCT01878643
Completed
Early Phase 1

Pilot Study of the Effects of Inhaled Antibiotic on Bacterial Resistance

Stony Brook University1 site in 1 country47 target enrollmentDecember 2001

Overview

Phase
Early Phase 1
Intervention
vancomycin or gentamicin
Conditions
Respiratory Infection
Sponsor
Stony Brook University
Enrollment
47
Locations
1
Primary Endpoint
Eradication of multi-drug resistant bacteria
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study was :

  • to determine the effect of inhaled antibiotics on airway bacteria in ventilated patients
  • to determine the effect of inhaled antibiotics on respiratory infection

Detailed Description

Double-blind randomized placebo controlled study examining the effect of aerosolized antibiotics on respiratory infection signs and symptoms and on bacterial eradication and resistance. Systemic antibiotics are administered by the responsible physician

Registry
clinicaltrials.gov
Start Date
December 2001
End Date
December 2002
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • be on mechanical ventilation greater than 3 days
  • greater than or equal to 18 years and survival greater than 14 days
  • organisms on Gram stain with increasing purulent secretions

Exclusion Criteria

  • pregnancy
  • allergy to drugs administered

Arms & Interventions

Drug: vancomycin or gentamicin

vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours

Intervention: vancomycin or gentamicin

Drug: Placebo

normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin

Intervention: Placebo

Outcomes

Primary Outcomes

Eradication of multi-drug resistant bacteria

Time Frame: Randomization and at end of treatment

Tracheal aspirates are taken at randomization. Randomization to drug is determined by the Gram stain(organisms are Gram-positive, Gram-negative or both). End of treatment culture, susceptibility and Gram stain of tracheal aspirate is taken after 14 days of treatment or at time of extubation, (which ever comes first). Eradication is defined as absence of growth in culture and absence of organisms on Gram stain.

Secondary Outcomes

  • Clinical Pulmonary Infection Score (CPIS)(Randomization and at end of treatment which is defined as 14 days or at time of extubation, which ever comes first.)

Study Sites (1)

Loading locations...

Similar Trials